Immune Pharmaceuticals
Monoclonal Antibody Treatment for Cancer and Inflammatory Diseases
Company Overview
Snapshot
Founded in July 2010 by Jean Kadouche, PhD, Immune Pharmaceuticals operates with 1–10 employees. The company has raised a total of $52.7 million across six funding rounds from three investors. In March 2014, Immune Pharmaceuticals completed an Initial Public Offering on NASDAQ, raising $11.7 million.
Business overview
Immune Pharmaceuticals Inc. is a biopharmaceutical company focused on developing novel therapeutic agents for immunologic and inflammatory diseases. Its core product, bertilimumab, is a first-in-class, fully human monoclonal antibody designed to target and lower eotaxin-1 levels, a chemokine involved in immune responses and eosinophil attraction to inflammation sites. By neutralizing eotaxin-1, bertilimumab aims to prevent eosinophil migration and alleviate associated inflammatory conditions. The company is currently conducting Phase 2 clinical trials for bertilimumab in patients with bullous pemphigoid and ulcerative colitis, with potential applications in atopic dermatitis, asthma, and other eosinophil-mediated diseases. Immune Pharmaceuticals operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, focusing on Drugs Discovery & Development and Drug Delivery.
Strategic signal
In December 2018, Immune Pharmaceuticals engaged. This move signaled the company's intent to explore partnerships or other strategic options to advance the development and commercialization of its key therapeutic asset, potentially indicating a shift towards maximizing value from its pipeline through external collaborations.
Log in to access full profile ›Company Intelligence Q&A
- What is Immune Pharmaceuticals' primary focus?
- Immune Pharmaceuticals is focused on developing novel therapeutic agents, particularly monoclonal antibodies, for the treatment of immunologic and inflammatory diseases, as well as cancer.
- What is bertilimumab?
- Bertilimumab is Immune Pharmaceuticals' lead product, a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine involved in immune responses and inflammation.
- When did Immune Pharmaceuticals conduct its Initial Public Offering?
- Immune Pharmaceuticals completed its Initial Public Offering on NASDAQ in March 2014, raising $11.7 million.
- What was a significant strategic move by Immune Pharmaceuticals in late 2018?
- In December 2018, Immune Pharmaceuticals engaged.
- What is the current status of Immune Pharmaceuticals?
- Immune Pharmaceuticals is currently non-active, having ceased to operate in March 2020, leading to its delisting from NASDAQ and OTC exchanges.